Skip to main content
. 2017 Oct 11;29(1):250–255. doi: 10.1093/annonc/mdx642

Figure 1.

Figure 1.

Percentage of patients with clinically significant toxicities with cytotoxic T-lymphocyte antigen 4 (CTLA-4)/programmed death 1 (PD-1) blockade (gold), recurrent toxicities with PD-1 blockade (blue), and distinct de novo toxicities with PD-1 blockade (red).